Neurology care
Auth57 · Specialty PA Pack

Neurology

For the neurologist managing MS and migraine therapies — coverage, criteria, and appeals across all 51 states.

Structured rules
1,002
PA-required
99%
Appeal layer
51/51
Criteria docs
44/51
The breadth · all 51 jurisdictions

Every state, quantified for neurology

StateApproved · CY25RulesPA-requiredAppealCriteria docs
● Recent · CY2025 disclosures — click a state to drill in
WAWashington▸ viewing88.2%23100%6
COColorado91.8%2195%10
OHOhio77.7%23100%14
All states · A–Z
AKAlaska13100%2
ALAlabama21100%6
ARArkansas23100%2
AZArizona21100%6
CACalifornia2396%7
CTConnecticut21100%3
DCDistrict of Columbia2195%9
DEDelaware20100%3
FLFlorida21100%
GAGeorgia2396%12
HIHawaii2195%5
IAIowa21100%6
IDIdaho15100%1
ILIllinois20100%
INIndiana21100%2
KSKansas20100%11
KYKentucky23100%3
LALouisiana19100%9
MAMassachusetts17100%1
MDMaryland1995%9
MEMaine19100%3
MIMichigan19100%6
MNMinnesota15100%2
MOMissouri25100%1
MSMississippi23100%8
MTMontana15100%2
NCNorth Carolina23100%6
NDNorth Dakota15100%
NENebraska19100%3
NHNew Hampshire19100%
NJNew Jersey19100%3
NMNew Mexico15100%3
NVNevada19100%16
NYNew York21100%3
OKOklahoma23100%
OROregon2295%3
PAPennsylvania19100%8
RIRhode Island15100%
SCSouth Carolina21100%7
SDSouth Dakota13100%
TNTennessee21100%4
TXTexas23100%39
UTUtah21100%11
VAVirginia2396%5
VTVermont13100%6
WIWisconsin21100%3
WVWest Virginia16100%1
WYWyoming15100%5
Deep dive· Washington

Washingtonneurology, every program

Click any state in the table above to drill into its rules, approval rates, and appeal path.

● Rules verified as-of Jun 8, 2026
Medicaid FFS · CY25
54.8%approved
Draft · aggregatedSource ↗Dental = ~78% of HCA fee-for-service PA volume and is dental-skewed; expedited EPAs aren't captured. Not representative of drug/medical PA. CY2025 data is preliminary.
Medicaid MCO · CY25
88.2%approved · 4 payers
Draft · aggregatedSource ↗
medicaid ffs
Approved · CMS-0057-F 202554.8%
Draft · aggregatedSource ↗Dental = ~78% of HCA fee-for-service PA volume and is dental-skewed; expedited EPAs aren't captured. Not representative of drug/medical PA. CY2025 data is preliminary.
  • MS disease-modifying therapiesPA required

    WA Medicaid PDL: non-preferred agents in this class require PA.

  • CGRP inhibitors · migrainePA required

    WA Medicaid PDL: non-preferred agents in this class require PA.

commercial regulated
  • CGRP inhibitors · migraine(UnitedHealthcare)PA required

    UnitedHealthcare commercial (Advantage 3-Tier). Antimigraine-migraines; CGRP agents (AIMOVIG, NURTEC, QULIPTA, UBRELVY, ZAVZPRET) carry PA+ST+QL; triptans QL only [e.g. AIMOVIG, EMGALITY, NURTEC, QULIPTA]

  • MS disease-modifying therapies(UnitedHealthcare)PA required

    UnitedHealthcare commercial (Advantage 3-Tier). CNS-multiple sclerosis; all agents carry PA+QL+SP (MAVENCLAD adds ST) [e.g. AVONEX, KESIMPTA, MAVENCLAD, MAYZENT]

  • CGRP inhibitors · migraine(Cigna)PA required

    Cigna commercial (Advantage 3-Tier). CGRP mAbs and gepants carry PA [e.g. AIMOVIG, AJOVY, EMGALITY, NURTEC ODT]

  • MS disease-modifying therapies(Cigna)PA required

    Cigna commercial (Advantage 3-Tier). MS DMTs SP, injectables/orals PA (generics SP only) [e.g. AVONEX, KESIMPTA, MAYZENT, VUMERITY]

  • CGRP inhibitors · migraine(Aetna (CVS Caremark))PA required

    Aetna (CVS Caremark) commercial formulary. CGRP monoclonal antibodies, specialty PA/ST [e.g. AIMOVIG, EMGALITY, AJOVY (CGRP mAbs)]

  • CGRP inhibitors · migraine(Anthem Blue Cross (Elevance))PA required

    Anthem Blue Cross (Elevance) commercial formulary. CGRP receptor antagonist monoclonal antibodies: PA + QL [e.g. EMGALITY galcanezumab, CGRP monoclonal antibodies]

  • MS disease-modifying therapies(Anthem Blue Cross (Elevance))PA required

    Anthem Blue Cross (Elevance) commercial formulary. MS agents (interferons, NRF2, pyrimidine synthesis, K-channel blockers, oral): PA + SP; monoclonal abs vary [e.g. teriflunomide, dimethyl fumarate, interferon beta, TYSABRI natalizumab]

part d
  • CGRP inhibitors · migraine(Centene)PA required

    Centene Part D (CMS formulary file, plan-grounded).

  • MS disease-modifying therapies(Centene)PA required

    Centene Part D (CMS formulary file, plan-grounded).

  • CGRP inhibitors · migraine(Unitedhealthcare)PA required

    Unitedhealthcare Part D (CMS formulary file, plan-grounded).

  • MS disease-modifying therapies(Unitedhealthcare)PA required

    Unitedhealthcare Part D (CMS formulary file, plan-grounded).

  • CGRP inhibitors · migraine(Humana)PA required

    Humana Part D (CMS formulary file, plan-grounded).

  • MS disease-modifying therapies(Humana)PA required

    Humana Part D (CMS formulary file, plan-grounded).

  • MS disease-modifying therapies(Cigna)PA required

    Cigna Part D (CMS formulary file, plan-grounded).

  • CGRP inhibitors · migraine(Cigna)PA required

    Cigna Part D (CMS formulary file, plan-grounded).

  • CGRP inhibitors · migraine(Aetna)PA required

    Aetna Part D (CMS formulary file, plan-grounded).

  • MS disease-modifying therapies(Aetna)PA required

    Aetna Part D (CMS formulary file, plan-grounded).

  • CGRP inhibitors · migraine(Kaiser)PA required

    Kaiser Part D (CMS formulary file, plan-grounded).

  • MS disease-modifying therapies(Kaiser)PA required

    Kaiser Part D (CMS formulary file, plan-grounded).

commercial qhp
  • MS disease-modifying therapies(Molina Healthcare)PA required

    Molina Healthcare commercial formulary. MS agents, interferons, and pyrimidine-synthesis inhibitor all PA

  • CGRP inhibitors · migraine(Molina Healthcare)PA required

    Molina Healthcare commercial formulary. Ubrelvy/Ajovy/Emgality (gepants + CGRP mAbs) carry PA

If denied in Washington
📨 Office of Administrative Hearings (OAH)
Unlock the full pack

Full criteria, sources & appeal paths — all 51 states.

You’ve seen the breadth and one state in full. The complete Neurologypack — every state’s criteria, source citations, and step-by-step appeal instructions — is one email away.

We'll never sell or share your email.

Assembled from Auth57’s rules + criteria corpus + 51-state appeal layer. Draft data — verify against the payer’s current policy before relying.